BidaskClub upgraded shares of Nantkwest (NASDAQ:NK) from a sell rating to a hold rating in a report published on Tuesday.
Several other research firms have also commented on NK. Raymond James Financial reaffirmed a hold rating on shares of Nantkwest in a research report on Monday, December 11th. Zacks Investment Research lowered Nantkwest from a buy rating to a hold rating in a research report on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $5.25.
Nantkwest (NASDAQ NK) opened at $4.60 on Tuesday. The company has a market capitalization of $366.29, a P/E ratio of -3.62 and a beta of 2.84. Nantkwest has a 12-month low of $2.71 and a 12-month high of $8.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47.
ILLEGAL ACTIVITY WARNING: “BidaskClub Upgrades Nantkwest (NK) to “Hold”” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://sportsperspectives.com/2018/03/10/bidaskclub-upgrades-nantkwest-nk-to-hold.html.
Nantkwest Company Profile
NantKwest, Inc is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.